The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
复制标题
DOI：
10.1016/s0960-894x(99)00288-7
复制
发表时间：
1999-07-05
影响因子：
2.7
通讯作者：
Patrick, D
中科院分区：
文献类型：
--
作者：
Prasit, P;Wang, Z;Patrick, D
描述了考克斯-2抑制剂罗非考昔（MK 966，Vioxx（R））的开发。它在体外和体内基本上与吲哚美辛等效，但没有由于考克斯-1抑制而引起的致溃疡副作用，（C）1999由Elsevier Science Ltd.出版。保留所有权利。
The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx(R)) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition, (C) 1999 Published by Elsevier Science Ltd. All rights reserved.